Putative Cognitive Enhancer VU319

Summary

Putative Cognitive Enhancer VU319 is a clinical trial^[1].

Key Facts

• Putative Cognitive Enhancer VU319 is in the country of United States^[2].
• Putative Cognitive Enhancer VU319's instance of is recorded as clinical trial^[3].
• Putative Cognitive Enhancer VU319's start time is recorded as +2017-07-28T00:00:00Z^[4].
• Putative Cognitive Enhancer VU319's end time is recorded as +2019-10-30T00:00:00Z^[5].
• Putative Cognitive Enhancer VU319's contributor to the creative work or subject is recorded as Vanderbilt University Medical Center^[6].
• Putative Cognitive Enhancer VU319's main subject is recorded as cognitive dysfunction^[7].
• Putative Cognitive Enhancer VU319's number of participants is recorded as {'unit': '1', 'amount': '+52'}^[8].
• Putative Cognitive Enhancer VU319's title is recorded as Study of the M1 Positive Allosteric Modulator VU0467319^[9].
• Putative Cognitive Enhancer VU319's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[10].
• Putative Cognitive Enhancer VU319's ClinicalTrials.gov ID is recorded as NCT03220295^[11].
• Putative Cognitive Enhancer VU319's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+55'}^[12].
• Putative Cognitive Enhancer VU319's clinical trial phase is recorded as phase I clinical trial^[13].
• Putative Cognitive Enhancer VU319's research site is recorded as Vanderbilt University^[14].
• Putative Cognitive Enhancer VU319's principal investigator is recorded as Paul A. Newhouse^[15].
• Putative Cognitive Enhancer VU319's study type is recorded as interventional study^[16].